The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has ... came following feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...

Whereas the latter derives most of its revenue from a few diabetes or obesity drugs, AstraZeneca has a large and diversified pipeline of medicines. The company's products span the field of ...